A pilot study of 21 patients with untreated inflammatory BC showed that bevacizumab decreased activated VEGFR-2 levels in tumour cells, increased tumour apoptosis, and reduced tumour blood perfusion, as measured by DCE-MRI [23]. This evidence concerns the gene KDR and neoplasm.